Jpmorgan Chase & CO Bio N Tech Se Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Bio N Tech Se stock. As of the latest transaction made, Jpmorgan Chase & CO holds 26,703 shares of BNTX stock, worth $2.89 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,703
Previous 49,719
46.29%
Holding current value
$2.89 Million
Previous $4 Million
20.63%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BNTX
# of Institutions
356Shares Held
38.3MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$899 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$489 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$472 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$205 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$196 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $26.3B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...